-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

678 GEM2017Fit Phase 3 Trial in Fit Elderly Patients (Aged 65-80) with Newly Diagnosed Myeloma: Impact of Daratumumab at Induction and/or Consolidation

Program: Oral and Poster Abstracts
Type: Oral
Session: 654. Multiple Myeloma: Pharmacologic Therapies: Optimizing Therapy in Newly Diagnosed Myeloma and Beyond
Hematology Disease Topics & Pathways:
Combination therapy, Plasma Cell Disorders, Diseases, Therapy sequence, Treatment Considerations, Lymphoid Malignancies
Sunday, December 8, 2024: 5:45 PM

Maria- Victoria Mateos1, Bruno Paiva, PhD2*, Maria Teresa Cedena Romero, MD, PhD3*, Noemi Puig, PhD4, Anna Sureda Balari5, Albert Oriol, MD, PhD6*, Enrique M Ocio, MD, PhD7*, Laura Rosiñol, MD, PhD8*, Yolanda González-Montes, MD, PhD9*, Joan Bargay, MD, PhD10*, Esther Gonzalez Garcia, MD, PhD11*, Miguel Teodoro Hernández Garcia, MD, PhD12*, Angel Ramirez, MD, PhD13*, Alexia Suarez-Cabrera, MD, PhD14*, María-Jesús Blanchard, MD, PhD15*, Sebastián Garzón, MD, PhD16*, Luis Felipe Casado17*, Valentin Cabanas Perianes, MD, PhD18*, Jaime Perez de Oteyza19*, Mercedes Gironella, MD20*, Joaquin Martínez-López21*, Ana-Isabel -Teruel, MD, PhD22*, Pilar Delgado, MD, PhD23*, Elena Prieto, MD, PhD24*, Juan-Jose Lahuerta Palacios, MD, PhD25*, Joan Bladé, MD, PhD26* and Jesús F. San-Miguel, MD, PhD27

1Hospital Universitario de Salamanca, Instituto de Investigación Biomédica de Salamanca (IBSAL), Centro de Investigación del Cáncer (IBMCC-USAL,CSIC), Salamanca, Spain
2Cancer Center Clinica Universidad de Navarra, Centro de Investigación Médica Aplicada (CIMA), IDISNA, CIBER-ONC number CB16/12/00369 and CB16/12/00489, Pamplona, Spain
3Instituto de Investigación IMAS12, Madrid, Spain
4Hospital Universitario de Salamanca (HUSAL), IBSAL, IBMCC (USAL-CSIC), CIBERONC, Salamanca, Spain
5Clinical Hematology Department, Institut Català d’Oncologia-Hospitalet, IDIBELL, Barcelona, Spain
6Hematology, Catalan Institute of Oncology and Josep Carreras Institute, Hospital Germans Trias i Pujol, Badalona, Spain
7Hospital Universitario Marqués de Valdecilla (IDIVAL), Universidad de Cantabria, Santander, Spain
8Hematology, IDIBAPS, Hospital Clinic, Barcelona, ESP
9Hematology, Institut d'Oncologia Dr. Josep Trueta, Girona, Spain
10Hematology, Hospital Universitari Son Llàtzer, IdIsBa, Palma de Mallorca, Spain
11Hematology, University Hospital Cabueñes, Gijón, Spain
12Hematology, Hospital Universitario de Canarias, Santa cruz de Tenerife, Spain
13Hematology, Hospital Central de Asturias, Oviedo, Spain
14Hospital Universitario de Gran Canaria Dr. Negrín, Las Palmas De Gran Canaria, Spain
15Hematology, Hospital Universitario Ramon y Cajal, Madrid, Spain
16Hematology, Hospital Universitario Jerez de la Frontera, Jerez de la Frontera, Cádiz, Spain
17Hematology, Hospital General Universitario de Toledo, Toledo, Spain
18Hematology, IMIB-Virgen de la Arrixaca University Hospital, University of Murcia, El Palmar, Murcia, Spain
19Clinical Hematology and Oncohematology, Hospital Universitario HM Sanchinarro, Madrid, Spain
20Hematology, Hospital Universitari Vall d'Hebron, Barcelona, Spain
21Department of Hematology, Hospital Universitario 12 de Octubre, Madrid, Spain
22Hematology, Hospital Clínico Universitario de Valencia, Valencia, Spain
23Hematology Department, Hospital Universitario Miguel Servet, Zaragoza, Spain
24Hematology Department, Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain
25Hematology, Hospital Universitario 12 de Octubre, Imas12, CIBERONC, Madrid, Spain
26Hematology, Hospital Clínic de Barcelona, Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), University of Barcelona; and GEM/PETHEMA, Barcelona, Spain
27Department of Hematology, Centre for Applied Medical Research, Cancer Center Clinica Universidad de Navarra, University of Navarra, IdiSNA, CIBERONC, Pamplona, Spain

Background: In patients with newly diagnosed multiple myeloma (NDMM) who are not candidates for transplant, VMP (bortezomib, melphalan, prednisone) and Rd (lenalidomide, dexamethasone) have been standard treatments. The Spanish Myeloma Group combined 9 cycles of VMP and 9 cycles of Rd, yielding good results for “fit” patients aged 65-80. They achieved a complete response (CR) rate of 47%, with 20% of patients being minimal residual disease negative (MRD-ve). The median progression-free survival (PFS) was 34 months, and the 4-year overall survival (OS) was 70%.

Patients and Study Design: Building on these results, we conducted a study comparing VMP9-Rd9 (control arm) with KRd (carfilzomib, lenalidomide, dexamethasone) and D-KRd (daratumumab, carfilzomib, lenalidomide, dexamethasone). The induction phase included 18 cycles, with the primary endpoint being the MRD-ve rate after induction. This primary endpoint was met, with significantly higher MRD-ve rates observed in both the KRd group [53.9%, Odds Ratio (OR) = 1.74, 95% CI: 1.39-2.16, p<0.001] and the D-KRd group [61.4%, OR = 2.03, 95% CI: 1.61-2.57, p<0.001] compared to the VMP9-Rd9 arm [26.6% (41 patients)].

The trial design included 4 DRd consolidation cycles for the two arms that have not anti-CD38 as part of the induction (VMP9-Rd9 and KRd arms) to evaluate if DRd consolidation might compensate for the absence of a monoclonal antibody during induction. Subsequently, patients were stratified by MRD status (positive or negative) for maintenance therapy with D-R vs. observation.

Frailty was evaluated using the Geriatric Assessment in Hematology (GAH) scale, considering patients younger than 80 years and with a score between 0 and 42 as fit.

We report the efficacy of the four consolidation cycles in the group of patients who initiated the consolidation phase and compared results with that of patients who completed induction in the D-KRd group and did not receive consolidation per protocol.

Results: A total of 462 patients were randomized, 101/154 patients in the VMP-Rd arm (64%) and 109/154 (68%) in the KRd arm reached consolidation phase, 109/154 patients (71%) in the D-KRd were evaluable after induction.

In the VMP9-Rd9 arm, 24 patients converted from MRD+ve to MRD-ve with consolidation, compared to 11 patients in the KRd arm. The MRD-ve rate was 62.2% in the VMP 9-Rd 9/DRd and 81.9% in the KRd/DRd. The MRD-ve rate was 85.3% in the D-KRd arm without consolidation, which was superior to the VMP9-Rd9-DRd arm [OR 2.33, 95% CI: 1.50-3.62, p<0.001] though not the KRD-DRd arm [OR1.12, 95% CI: 0.89-1.42, p=0.19]. In terms of serological responses in the group of patients who received consolidation, the stringent complete response (sCR)/CR rate was higher for KRd-DRd (81%) and D-KRd without consolidation (80.8%) compared to the control VMP9-Rd9 with DRd (61.6%). At 48 month and in the Intent To Treat population the proportion of patients alive and progression-free remained significantly higher in KRd-DRd (71%, p=0.009) and D-KRd without consolidation (69%, p=0.032) compared to the control arm (52.2%).

Regarding hematological toxicity during consolidation, no significant differences were reported between the two arms that received 4 DRd cycles. The only Grade 3/4 hematological adverse event (AE) reported in ≥10% of patients was neutropenia, observed in 27% of patients after VMP9-Rd9 and 24% after KRd. None of the Grade 3/4 non-hematological AEs were reported in more than 10% of patients. Infections of any grade were reported with DRd in 29% of patients after VMP9-Rd9 and in 25% after KRd. Neutropenia led to dose reductions in 40% of patients in both arms.

Conclusion: The trial met its primary endpoint. Consolidation with 4 DRd cycles deepened the MRD-ve rate in both VMP 9-Rd 9 and KRd arms. Nevertheless, the control arm (VMP9-Rd9) continue to remain inferior to KRD+ DRd and D-KRd without consolidation, with the latter two schemes being equivalent. Further analysis may identify specific subgroups of patients would benefit more from each of the two latter combination. The safety profile is manageable, and the trial is ongoing to evaluate long-term outcomes.

Disclosures: Mateos: Amgen, Takeda, Regeneron: Honoraria; BMS/Celgene, Janssen-Cilag, Sanofi, Abbvie, Stemline, Oncopeptides, GSK: Honoraria, Membership on an entity's Board of Directors or advisory committees. Paiva: Adaptive, Amgen, Becton Dickinson, Bristol Myers Squibb/Celgene, Janssen, Merck, Novartis, Roche, Sanofi and Takeda: Honoraria; Aztra Zeneca, Bristol Myers Squibb/Celgene, EngMab, Roche, Sanofi, and Takeda: Research Funding; Bristol Myers Squibb/Celgene, Janssen, Sanofi, and Takeda: Consultancy. Cedena Romero: JANSSEN: Honoraria. Puig: Pfizer, Sanofi, Amgen, BMS, Janssen, Takeda, and The Binding Site: Honoraria; Pfizer, Sanofi, Amgen, BMS-Celgene, Janssen, and Takeda: Consultancy. Sureda Balari: Roche: Honoraria, Other: Travel Expenses; Janssen: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; MSD: Consultancy, Honoraria, Speakers Bureau; BMS/Celgene: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: Travel Expenses, Research Funding, Speakers Bureau; Takeda Pharmaceutical: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: Travel Expenses, Research Funding, Speakers Bureau; Sanofi: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Amgen: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Gilead Kite: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Novartis: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Alexion: Honoraria; GETH-TC: Other: President; EBMT: Other: President; GSK: Consultancy, Honoraria, Speakers Bureau; Mundipharma: Consultancy; Bluebird: Membership on an entity's Board of Directors or advisory committees. Oriol: Oncopeptides: Membership on an entity's Board of Directors or advisory committees; Janssen: Honoraria, Membership on an entity's Board of Directors or advisory committees; Pfizer: Membership on an entity's Board of Directors or advisory committees; Sanofi: Honoraria, Membership on an entity's Board of Directors or advisory committees; Menarini: Membership on an entity's Board of Directors or advisory committees; Bristol Myers Squibb: Honoraria, Membership on an entity's Board of Directors or advisory committees; GlaxoSmithKline: Membership on an entity's Board of Directors or advisory committees. Ocio: Bristol-Myers Squibb: Consultancy, Honoraria; Oncopeptides: Consultancy, Honoraria; Takeda: Consultancy, Honoraria; GSK: Consultancy, Honoraria; Regeneron: Honoraria; Pfizer: Consultancy, Honoraria; Menarini: Consultancy, Honoraria; AbbVie: Consultancy, Honoraria; Amgen: Consultancy, Honoraria; Sanofi: Consultancy, Honoraria; Johnson & Johnson - Janssen: Consultancy, Honoraria, Speakers Bureau. Rosiñol: Janssen, BMS, Amgen, Takeda, GSK, Menarini, Sanofi: Honoraria. Hernández Garcia: BMS/Celgene, Janssen-Cilag, Amgen, Takeda, GSK: Consultancy. Ramirez: GSK: Honoraria; Incyte: Honoraria; Takeda: Consultancy, Honoraria; Sanofi: Honoraria; AstraZeneca: Consultancy, Honoraria; Abbvie: Consultancy, Honoraria; EUSA Pharma: Honoraria; Roche: Consultancy, Honoraria; Novartis: Consultancy, Honoraria; BMS: Consultancy, Honoraria; Janssen-Cilag, S.A.: Consultancy, Honoraria; Pfizer: Consultancy; Gilead: Consultancy; Beigene: Consultancy. Casado: Janssen, Roche, Novartis, BMS, Amgen, Takeda, Pfizer, Incyte, Abbvie, GSK, Sanofi, BeiGene: Honoraria; Janssen, Roche, Novartis, BMS, Amgen, Takeda, Pfizer, Incyte, Abbvie, GSK, Sanofi, BeiGene, Loxo, ELVN: Research Funding; Janssen, Roche, Novartis, BMS, Amgen, Takeda, Pfizer, Incyte, Abbvie, GSK, Sanofi, BeiGene: Consultancy. Perez de Oteyza: Regeneron Pharmaceuticals, Inc.: Research Funding; Roche: Consultancy, Speakers Bureau; Janssen: Consultancy. Gironella: Beigene, GSK, Janssen-Cilag: Consultancy. Martínez-López: Altum Sequencing: Current equity holder in private company; Pfizer: Honoraria; Janssen: Honoraria. Lahuerta Palacios: Sanofi: Honoraria; BMS: Honoraria; Janssen: Honoraria. Bladé: Amgen: Other: Honoraria for lectures; Janssen: Other: Honoraria for lectures; Celgene/Bristol Myers Squibb: Other: Honoraria for lectures; Sanofi: Other: Honoraria for lectures. San-Miguel: Amgen: Consultancy, Other: Advisory Board ; Abbvie: Consultancy, Other: Advisory Board; Roche: Other: Advisory board; Regeneron: Other: Advisory board; Takeda: Other: Advisory board; MSD: Other: Advisory board; Janssen-Cilag: Other: Advisory board; Celgene: Other: Advisory board; Karyopharm: Other: Advisory board; Bristol Myers Squibb: Other: Advisory board; GlaxoSmithKline: Other: Advisory board; Haemalogix: Other: Advisory board; Novartis: Other; Sanofi: Other: Advisory board; SecuraBio: Other: Advisory board.

<< Previous Abstract | Next Abstract
*signifies non-member of ASH